Revance Therapeutics 获得了其颈部肌张力障碍治疗药物 DAXXIFY 的永久 J 代码，并在 Neurology® 上发表了积极的 ASPEN-1 Pivotal 3 期研究结果。 Revance Therapeutics receives permanent J-code for DAXXIFY, its cervical dystonia treatment, with positive ASPEN-1 Pivotal Phase 3 study results published in Neurology®.
Revance Therapeutics, Inc. 的产品 DAXXIFY 已获得永久 J 代码，该产品适用于治疗成人颈肌张力障碍。 Revance Therapeutics, Inc. has received a permanent J-code for its product DAXXIFY, which is indicated for the treatment of cervical dystonia in adults. J 代码由商业保险计划、医疗保险和其他政府付款人用于报销目的。 J-Codes are used by commercial insurance plans, Medicare, and other government payers for reimbursement purposes. 此外，Revance 还宣布发表 Neurology® 中的 ASPEN-1 Pivotal 3 期研究结果，强化了该产品的长效持续时间和良好的安全性。 In addition, Revance announced the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, reinforcing the product's long duration of effect and favorable safety profile.